Henry Ford Health System Receives $16 Million Gift to Benefit Henry Ford Pancreatic Cancer Center

Henry Ford Health System today announced a $16 million gift to its Henry Ford Pancreatic Cancer Center (HFPCC), which was launched in 2018 by an initial $20 million gift from the same donor, who wishes to remain anonymous. The gift will bolster the HFPCC’s clinical and translational research endeavors in the fight against this devastating disease, for which the five-year survival rate is only 9 percent.

Read more

New Research in JNCCN Evaluates Cost-Effectiveness of Olaparib, a PARP Inhibitor, for Metastatic Pancreatic Cancer

New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.

Read more

Expert alert: Changing the outlook for pancreatic cancer

Pancreatic cancer often is hidden and doesn’t cause symptoms until it has spread. It is a leading cause of cancer deaths in the world.

November 19 is World Pancreatic Cancer Day, but the entire month of November is meant to bring awareness to this disease.

Advances in screening and early detection for high-risk people, minimally invasive surgical innovations and new genetic classifications are changing the outlook for pancreatic cancer, says Dr. Michael Wallace, a Mayo Clinic gastroenterologist.

Read more

Moderate-pace Walking Shrunk Pancreatic Cancer Tumors and Increased Cancer-killing Cells, Small Study Shows

Emily LaVoy, PhD, of the University of Houston, and colleagues explored the effects of moderate-intensity exercise on a mouse model of pancreatic cancer. Pancreatic cancer can be a particularly dangerous form of cancer because it is often diagnosed in later stages and spreads quickly. Though the trial sample was small—thus warranting further study—the results were optimistic.

Read more